Galderma Laboratories, LP, has announced the publication of the long-term efficacy and safety results of a 1-year, open-label, non-comparative study of Mirvaso® (brimonidine) Topical Gel, 0.33% in patients with moderate

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field